Avalo Therapeutics (AVTX) Assets Average (2015 - 2026)

Avalo Therapeutics (AVTX) has 12 years of Assets Average data on file, last reported at $108.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 25.21% year-over-year to $108.2 million; the trailing twelve-month figure through Mar 2026 stood at $108.2 million (down 25.21% YoY), and the FY2025 full-year result was $133.6 million, up 55.59% from the prior year.
• Assets Average for Q1 2026 stood at $108.2 million, down from $120.8 million in the prior quarter.
• Across five years, Assets Average topped out at $144.6 million in Q1 2025 and bottomed at $25.1 million in Q4 2023.
• The 5-year median for Assets Average is $72.4 million (2024), against an average of $79.6 million.
• The widest annual swing landed in 2022, when Assets Average plunged 60.18%; it then soared 395.77% in 2024.
• A 5-year view of Assets Average shows it stood at $35.0 million in 2022, then slipped by 28.11% to $25.1 million in 2023, then surged by 395.77% to $124.6 million in 2024, then retreated by 3.06% to $120.8 million in 2025, then fell by 10.44% to $108.2 million in 2026.
• The last three Assets Average figures came in at $108.2 million (Q1 2026), $120.8 million (Q4 2025), and $125.8 million (Q3 2025), per Business Quant data.

Peer Comparison